- In July 2024, Agilent Technologies has announced the acquisition of Canadian drug services firm BioVectra for USD 925 million. This move expands Agilent's capabilities in gene editing, specifically in manufacturing oligonucleotides and peptides, enhancing its role in RNA-based therapies and gene editing technologies like CRISPR-Cas
- In June 2024, Thermo Fisher celebrated the ribbon-cutting of a 72,500-square-foot expansion at its Middleton campus, which will serve as a laboratory for pharmaceutical testing. The project will create 350 jobs over the next two years, with state tax credits supporting the initiative
- In November 2024, Sartorius Stedim Biotech has opened a new Center for Bioprocess Innovation in Marlborough, Massachusetts, aimed at advancing the development of next-generation therapeutics. The 63,000-square-foot facility will provide process optimization, training, and GMP suites for clinical production starting in 2025
- In March 2024, Beckman Coulter Life Sciences has launched the CytoFLEX nano Flow Cytometer, a breakthrough in nanoparticle analysis that enables detection as small as 40 nm. This system enhances sensitivity, offering up to 50% more data for research into extracellular vesicles and lower-abundance targets
- In March 2024, Beckman Coulter Life Sciences has received FDA 510(k) clearance to distribute its DxFLEX Clinical Flow Cytometer in the U.S. This simplifies high-complexity testing with enhanced sensitivity and automated compensation, making multicolor flow cytometry more accessible and efficient for labs
